Unknown

Dataset Information

0

Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice.


ABSTRACT:

Rationale

Fibroblast growth factor-10 (FGF10) controls survival, proliferation, and differentiation of distal-alveolar epithelial progenitor cells during lung development.

Objectives

To test for the protective and regenerative effect of Fgf10 overexpression in a bleomycin-induced mouse model of pulmonary inflammation and fibrosis.

Methods

In SP-C-rtTA; tet(O)Fgf10 double-transgenic mice, lung fibrosis was induced in 2-month-old transgenic mice by subcutaneous delivery of bleomycin (BLM), using an osmotic minipump for 1 week. Exogenous Fgf10 expression in the alveolar epithelium was induced for 7 days with doxycycline during the first, second, and third weeks after bleomycin pump implantation, and lungs were examined at 28 days.

Measurements and main results

Fgf10 overexpression during Week 1 (inflammatory phase) resulted in increased survival and attenuated lung fibrosis score and collagen deposition. In these Fgf10-overexpressing mice, an increase in regulatory T cells and a reduction in both transforming growth factor-beta(1) and matrix metalloproteinase-2 activity were observed in bronchoalveolar lavage fluids whereas the number of surfactant protein C (SP-C)-positive, alveolar epithelial type II cells (AEC2) was markedly elevated. Analysis of SP-C and TUNEL (terminal deoxynucleotidyltransferase dUTP nick end labeling) double-positive cells and isolation of AEC2 from lungs overexpressing Fgf10 demonstrated increased AEC2 survival. Expression of Fgf10 during Weeks 2 and 3 (fibrotic phase) showed significant attenuation of the lung fibrosis score and collagen deposition.

Conclusions

In the bleomycin model of lung inflammation and fibrosis, Fgf10 overexpression during both the inflammatory and fibrotic phases results in a greatly reduced extent of lung fibrosis, suggesting that FGF10 may be useful as a novel approach to the treatment of pulmonary fibrosis.

SUBMITTER: Gupte VV 

PROVIDER: S-EPMC2742760 | BioStudies | 2009-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6662701 | BioStudies
2019-01-01 | S-EPMC6524168 | BioStudies
2011-01-01 | S-EPMC3248478 | BioStudies
2019-01-01 | S-EPMC6675554 | BioStudies
1000-01-01 | S-EPMC2957416 | BioStudies
2019-03-30 | GSE129079 | GEO
2013-01-01 | S-EPMC3826270 | BioStudies
2020-01-01 | S-EPMC7288553 | BioStudies
| S-EPMC3135847 | BioStudies
| S-EPMC7533251 | BioStudies